{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:49:22Z","timestamp":1793746162528,"version":"4.6.1"},"reference-count":215,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2017,12,1]],"date-time":"2017-12-01T00:00:00Z","timestamp":1512086400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1016\/j.jhep.2017.07.011","type":"journal-article","created":{"date-parts":[[2017,7,21]],"date-time":"2017-07-21T02:45:22Z","timestamp":1500605122000},"page":"1281-1297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":162,"title":["How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?"],"prefix":"10.1016","volume":"67","author":[{"given":"Neil","family":"Rajoriya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Combet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabien","family":"Zoulim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2017.07.011_b0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0140-6736(09)60207-5","article-title":"Hepatitis B virus infection","volume":"373","author":"Liaw","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.07.011_b0010","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.cld.2010.05.007","article-title":"Natural history of chronic hepatitis B","volume":"14","author":"McMahon","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1055\/s-2003-37590","article-title":"Natural history and prognosis of hepatitis B","volume":"23","author":"Fattovich","year":"2003","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0020","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0025","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1053\/j.gastro.2016.07.012","article-title":"HBV DNA integration and clonal hepatocyte expansion in chronic hepatitis B patients considered immune tolerant","volume":"151","author":"Mason","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0030","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1002\/hep.22878","article-title":"Long-term outcome of hepatitis B e antigen-negative hepatitis B surface antigen carriers in relation to changes of alanine aminotransferase levels over time","volume":"49","author":"Tai","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0035","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2893.2011.01450.x","article-title":"Serial HBV DNA levels in patients with persistently normal transaminase over 10 years following spontaneous HBeAg seroconversion","volume":"19","author":"Chen","year":"2012","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0040","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/j.jhep.2008.07.014","article-title":"Statements from the Taormina expert meeting on occult hepatitis B virus infection","volume":"49","author":"Raimondo","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0045","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jhep.2012.02.010","article-title":"European Association for the Study of the Liver (EASL) clinical practice guidelines: Management of chronic hepatitis B virus infection","volume":"57","author":"Papatheodoridis","year":"2012","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0050","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1053\/jhep.2002.33638","article-title":"Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B","volume":"35","author":"Hsu","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0055","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1053\/gast.2002.36026","article-title":"Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection","volume":"123","author":"Chen","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0060","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/jmv.10534","article-title":"Hepatitis B virus genotypes and spontaneous hepatitis B e antigen seroconversion in Taiwanese hepatitis B carriers","volume":"72","author":"Kao","year":"2004","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0065","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1126\/science.8211155","article-title":"From hepatitis to hepatoma: lessons from type B viral hepatitis","volume":"262","author":"Chen","year":"1993","journal-title":"Science"},{"key":"10.1016\/j.jhep.2017.07.011_b0070","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1159\/000360947","article-title":"Genotypes and genetic variability of hepatitis B virus","volume":"57","author":"Kramvis","year":"2014","journal-title":"Intervirology"},{"key":"10.1016\/j.jhep.2017.07.011_b0075","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.meegid.2013.03.021","article-title":"Hepatitis B virus subgenotyping: history, effects of recombination, misclassifications, and corrections","volume":"30","author":"Shi","year":"2013","journal-title":"Infec Gen Evol"},{"key":"10.1016\/j.jhep.2017.07.011_b0080","doi-asserted-by":"crossref","first-page":"5427","DOI":"10.3748\/wjg.v20.i18.5427","article-title":"Hepatitis B virus genotypes: global distribution and clinical importance","volume":"20","author":"Sunbul","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.07.011_b0085","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.meegid.2011.04.017","article-title":"Hepatitis B virus infection from an evolutionary point of view: how viral, host, and environmental factors shape genotypes and subgenotypes","volume":"11","author":"Araujo","year":"2011","journal-title":"Infec Genet Evol"},{"key":"10.1016\/j.jhep.2017.07.011_b0090","doi-asserted-by":"crossref","first-page":"a021436","DOI":"10.1101\/cshperspect.a021436","article-title":"Hepatitis B virus genotypes and variants","volume":"5","author":"Lin","year":"2015","journal-title":"Cold Spring Harb Perspect Med."},{"key":"10.1016\/j.jhep.2017.07.011_b0095","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jhep.2016.01.027","article-title":"Overview of hepatitis B viral replication and genetic variability","volume":"64","author":"Tong","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0100","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1440-1746.2002.02737.x","article-title":"Hepatitis B viral genotypes: clinical relevance and molecular characteristics","volume":"17","author":"Kao","year":"2002","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0105","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/infdis\/142.1.67","article-title":"Experimental transmission of hepatitis B virus by semen and saliva","volume":"142","author":"Scott","year":"1980","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0110","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/oxfordjournals.aje.a112370","article-title":"The e antigen and vertical transmission of hepatitis B surface antigen","volume":"105","author":"Beasley","year":"1977","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2017.07.011_b0115","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/infdis\/151.4.599","article-title":"Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state","volume":"151","author":"McMahon","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0120","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1086\/497837","article-title":"Application of hepatitis B virus genotyping and phylogenetic analysis in intrafamilial transmission of hepatitis B virus","volume":"41","author":"Lin","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0125","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1128\/AAC.43.8.1947","article-title":"Emergence of drug-resistant populations of woodchuck hepatitis virus in woodchucks treated with the antiviral nucleoside lamivudine","volume":"43","author":"Zhou","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jhep.2017.07.011_b0130","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1007\/PL00000061","article-title":"Constrained evolution with respect to gene overlap of hepatitis B virus","volume":"44","author":"Mizokami","year":"1997","journal-title":"J Mol Evol"},{"key":"10.1016\/j.jhep.2017.07.011_b0135","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.virol.2013.02.027","article-title":"Influence of overlapping genes on the evolution of human hepatitis B virus","volume":"441","author":"Torres","year":"2013","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2017.07.011_b0140","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1099\/jgv.0.000307","article-title":"Different patterns of codon usage in the overlapping polymerase and surface genes of hepatitis B virus suggest a de novo origin by modular evolution","volume":"96","author":"Pavesi","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0145","doi-asserted-by":"crossref","first-page":"D566","DOI":"10.1093\/nar\/gks1022","article-title":"HBVdb: a knowledge database for Hepatitis B Virus","author":"Hayer","year":"2013","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jhep.2017.07.011_b0150","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.meegid.2015.08.024","article-title":"Hepatitis B virus intergenotypic recombinants worldwide: an overview","volume":"36","author":"Araujo","year":"2015","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jhep.2017.07.011_b0155","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s11262-008-0205-5","article-title":"Complete genomic sequence and phylogenetic relatedness of hepatitis B virus isolates in Cambodia","volume":"36","author":"Huy","year":"2008","journal-title":"Virus Genes"},{"key":"10.1016\/j.jhep.2017.07.011_b0160","doi-asserted-by":"crossref","first-page":"10538","DOI":"10.1128\/JVI.00462-09","article-title":"A genetic variant of hepatitis B virus divergent from known human and ape genotypes isolated from a Japanese patient and provisionally assigned to new genotype","volume":"83","author":"Tatematsu","year":"2009","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0165","doi-asserted-by":"crossref","first-page":"8241","DOI":"10.1128\/JVI.00793-08","article-title":"When should \u201cI\u201d consider a new hepatitis B virus genotype?","volume":"82","author":"Kurbanov","year":"2008","journal-title":"J Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0170","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1056\/NEJM197610212951701","article-title":"Type B hepatitis: the infectivity of blood positive for e antigen and DNA polymerase after accidental needlestick exposure","volume":"295","author":"Alter","year":"1976","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0175","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/S0140-6736(89)90713-7","article-title":"Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection","volume":"334","author":"Carman","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.07.011_b0180","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1055\/s-2008-1073114","article-title":"Etiologies of acute liver failure","volume":"28","author":"Lee","year":"2008","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0185","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cld.2009.11.013","article-title":"Management of acute hepatitis B","volume":"14","author":"Schiffman","year":"2010","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0190","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.cld.2004.02.005","article-title":"Hepatitis B virus infection: co-infection with hepatitis C virus, hepatitis D virus, and human immunodeficiency virus","volume":"8","author":"Shukla","year":"2004","journal-title":"Clin Liver Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0195","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1056\/NEJM199106133242405","article-title":"A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis","volume":"324","author":"Liang","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0200","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1056\/NEJM199106133242404","article-title":"Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis","volume":"324","author":"Omata","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0205","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/0016-5085(95)90651-7","article-title":"Hepatitis B virus core promoter sequence analysis in fulminant and chronic hepatitis B","volume":"109","author":"Laskus","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0210","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/0016-5085(93)90425-C","article-title":"Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis","volume":"104","author":"F\u00e9ray","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0215","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s00535-008-2197-2","article-title":"Association of hepatitis B virus subgenotypes and basal core promoter\/precore region variants with the clinical features of patients with acute hepatitis","volume":"43","author":"Hayashi","year":"2008","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.07.011_b0220","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2893.2005.00581.x","article-title":"Clinical outcome and virological characteristics of hepatitis B-related acute liver failure in the United States","volume":"12","author":"Wai","year":"2005","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0225","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.ijmm.2015.08.016","article-title":"Studies of nosocomial outbreaks of hepatitis B in nursing homes in Germany suggest a major role of hepatitis B e antigen expression in disease severity and progression","volume":"305","author":"Seiz","year":"2015","journal-title":"Int J Med Microbiol"},{"key":"10.1016\/j.jhep.2017.07.011_b0230","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12985-015-0313-5","article-title":"Associations between hepatitis B virus basal core promoter\/pre-core region mutations and the risk of acute-on-chronic liver failure: a meta-analysis","volume":"12","author":"Hu","year":"2015","journal-title":"Virol J"},{"key":"10.1016\/j.jhep.2017.07.011_b0235","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/s12072-008-9106-x","article-title":"Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL)","volume":"3","author":"Sarin","year":"2009","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0240","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0140-6736(93)91736-6","article-title":"Acute liver failure: redefining the syndromes","volume":"342","author":"O'Grady","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.07.011_b0245","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.2169\/internalmedicine.47.1061","article-title":"Lamivudine treatment improves the prognosis of fulminant hepatitis B","volume":"47","author":"Miyake","year":"2008","journal-title":"Intern Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0250","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2893.2005.00695.x","article-title":"Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience","volume":"13","author":"Tillmann","year":"2006","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0255","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1136\/gut.2008.157149","article-title":"Risk factors for acute hepatitis B and its progression to chronic hepatitis in Shanghai, China","volume":"57","author":"Zhang","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b0260","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/jgh.13536","article-title":"Concurrent fatty liver increases risk of hepatocellular carcinoma among patients with chronic hepatitis B","volume":"32","author":"Chan","year":"2017","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0265","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2016.10.031","article-title":"Prognosis of patients with chronic hepatitis B in France (2008\u20132013): A nationwide, observational and hospital-based study","volume":"66","author":"Mallet","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0270","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1055\/s-2006-939751","article-title":"Hepatitis Be antigen negative chronic hepatitis B \u2013 Natural history and treatment","volume":"26","author":"Hadziyannis","year":"2006","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0275","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1056\/NEJMra031087","article-title":"Hepatitis B virus infection \u2013 natural history and clinical consequences","volume":"350","author":"Ganem","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0280","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1053\/gast.2002.33588","article-title":"Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C","volume":"122","author":"Chu","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0285","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2893.2006.00810.x","article-title":"Chronic hepatitis B virus infection acquired in childhood: special emphasis on prognostic and therapeutic implication of delayed HBeAg seroconversion","volume":"14","author":"Chu","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0290","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1053\/j.gastro.2004.09.048","article-title":"Clinical relevance of hepatitis B virus genotype in children with chronic infection and hepatocellular carcinoma","volume":"127","author":"Ni","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0295","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1053\/jhep.2003.50036","article-title":"Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease","volume":"37","author":"Sumi","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0300","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1128\/JCM.41.3.1277-1279.2003","article-title":"Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients","volume":"41","author":"Chan","year":"2003","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2017.07.011_b0305","doi-asserted-by":"crossref","first-page":"5036","DOI":"10.1128\/JCM.42.11.5036-5040.2004","article-title":"Longitudinal study of hepatitis activity and viral replication before and after HBeAg seroconversion in chronic hepatitis B patients infected with genotypes B and C","volume":"42","author":"Yuen","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.jhep.2017.07.011_b0310","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1440-1746.2004.03572.x","article-title":"Comparative study of genotype B and C hepatitis B virus-induced chronic hepatitis in relation to the basic core promoter and precore mutations","volume":"20","author":"Watanabe","year":"2005","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0315","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1053\/gast.2002.37041","article-title":"Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients","volume":"123","author":"S\u00e1nchez-Tapias","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0320","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3322\/canjclin.55.2.74","article-title":"The global health burden of infection-associated cancers in the year 2002","volume":"55","author":"Parkin","year":"2005","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.jhep.2017.07.011_b0325","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.jhep.2010.02.035","article-title":"Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos (t) ide therapy: a systematic review","volume":"53","author":"Papatheodoridis","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0330","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jhep.2015.01.002","article-title":"Risk of hepatocellular carcinoma in chronic hepatitis B: assessment and modification with current antiviral therapy","volume":"62","author":"Papatheodoridis","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0335","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/gut.2010.221846","volume":"60","author":"Papatheodoridis","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b0340","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/S1470-2045(11)70077-8","article-title":"Kim DY, on behalf of the REACH-B Working Group. Risk estimation for hepatocellular carcinoma in chronic hepatitis B (REACH-B): development and validation of a predictive score","volume":"12","author":"Yang","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jhep.2017.07.011_b0345","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1200\/JCO.2009.26.2675","article-title":"Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers","volume":"28","author":"Wong","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2017.07.011_b0350","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jhep.2008.07.023","article-title":"Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B","volume":"50","author":"Yuen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0355","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/jnci\/djn243","article-title":"Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma","volume":"100","author":"Yang","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2017.07.011_b0360","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1093\/carcin\/bgm301","article-title":"Role of hepatitis B virus genotype mixture, subgenotypes C2 and B2 on hepatocellular carcinoma: compared with chronic hepatitis B and asymptomatic carrier state in the same area","volume":"29","author":"Yin","year":"2008","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhep.2017.07.011_b0365","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0016-5085(00)70261-7","article-title":"Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B","volume":"118","author":"Kao","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0370","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/jnci\/dji043","article-title":"Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men","volume":"97","author":"Yu","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2017.07.011_b0375","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s10620-009-1083-y","article-title":"Clinical significance of genotypes and precore\/basal core promoter mutations in HBV related chronic liver disease patients in North India","volume":"55","author":"Sharma","year":"2010","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2017.07.011_b0380","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1200\/JCO.2007.13.2043","article-title":"High viral load and hepatitis B virus subgenotype ce are associated with increased risk of hepatocellular carcinoma","volume":"26","author":"Chan","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2017.07.011_b0385","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1111\/apt.12207","article-title":"Meta-analysis: The association of hepatitis B virus genotypes and hepatocellular carcinoma","volume":"37","author":"Wong","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0390","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1093\/jnci\/djp180","article-title":"Associations between hepatitis B virus mutations and the risk of hepatocellular carcinoma: a meta-analysis","volume":"101","author":"Liu","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.jhep.2017.07.011_b0395","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0168-8278(00)80279-2","article-title":"Rapid detection of genotypes and mutations in the pre-core promoter and the pre-core region of hepatitis B virus genome: correlation with viral persistence and disease severity","volume":"33","author":"Grandjacques","year":"2000","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0400","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1111\/j.1440-1746.2006.04515.x","article-title":"Association of pre-S deletion mutant of hepatitis B virus with risk of hepatocellular carcinoma","volume":"22","author":"Lin","year":"2007","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0405","first-page":"171","article-title":"Clinical significance of hepatitis B virus Pre-S deletion mutants in patients with chronic hepatitis B virus infection: a case control study","volume":"26","author":"Lin","year":"2009","journal-title":"Gastroenterol J Taiwan"},{"key":"10.1016\/j.jhep.2017.07.011_b0410","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/0168-8278(91)90036-B","article-title":"Replicating and virion secreting hepatitis B mutant virus unable to produce preS2 protein","volume":"13","author":"Fernholz","year":"1991","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0415","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/0042-6822(91)90984-J","article-title":"Hepatitis B defective virus with rearrangements in the preS gene during chronic HBV infection","volume":"183","author":"Gerken","year":"1991","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2017.07.011_b0420","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1111\/j.1440-1746.2008.05348.x","article-title":"Ground glass hepatocytes contain pre-S mutants and represent preneoplastic lesions in chronic hepatitis B virus infection","volume":"23","author":"Su","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0425","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1006\/viro.2001.1239","article-title":"Hypermodification and immune escape of an internally deleted middle-envelope (M) protein of frequent and predominant hepatitis B virus variants","volume":"292","author":"Tai","year":"2002","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2017.07.011_b0430","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1093\/carcin\/bgh207","article-title":"Pre-S mutant surface antigens in chronic hepatitis B virus infection induce oxidative stress and DNA damage","volume":"25","author":"Hsieh","year":"2004","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.jhep.2017.07.011_b0435","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.25592","article-title":"Impact of hepatitis B virus (HBV) preS\/S genomic variability on HBV surface antigen and HBV DNA serum levels","volume":"56","author":"Pollicino","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0440","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1053\/j.gastro.2006.01.011","article-title":"High prevalence and mapping of pre-S deletion in hepatitis B virus carriers with progressive liver diseases","volume":"130","author":"Chen","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0445","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/j.1478-3231.2012.02826.x","article-title":"Fine mapping of hepatitis B virus pre-S deletion and its association with hepatocellular carcinoma","volume":"32","author":"Kao","year":"2012","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0450","doi-asserted-by":"crossref","first-page":"2437","DOI":"10.1200\/JCO.2009.27.4456","article-title":"Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection","volume":"28","author":"Yang","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jhep.2017.07.011_b0455","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(05)17701-0","article-title":"Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial","volume":"365","author":"Janssen","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2017.07.011_b0460","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1111\/j.1572-0241.2006.00418.x","article-title":"Treatment with Peg-interferon \u03b1-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype","volume":"101","author":"Flink","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.07.011_b0465","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1053\/j.gastro.2009.08.061","article-title":"Factors that predict response of patients with hepatitis B e antigen\u2013Positive chronic hepatitis B to peginterferon-alfa","volume":"137","author":"Buster","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0470","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/(SICI)1096-9071(199601)48:1<8::AID-JMV2>3.0.CO;2-E","article-title":"Analysis of hepatitis B virus genotypes and pre-core region variability during interferon treatment of HBe antigen negative chronic hepatitis B","volume":"48","author":"Zhang","year":"1996","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0475","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1002\/jmv.21588","article-title":"Response to antiviral treatment in patients infected with hepatitis B virus genotypes E-H","volume":"81","author":"Erhardt","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0480","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1053\/jhep.2002.32096","article-title":"Hepatitis B e antigen in sera from individuals infected with hepatitis B virus of genotype G","volume":"35","author":"Kato","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0485","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1099\/vir.0.2008\/005124-0","article-title":"Hepatitis B virus genotype G epidemiology and co-infection with genotype A in Canada","volume":"89","author":"Osiowy","year":"2008","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0490","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2893.2010.01397.x","article-title":"HBsAg-negative mono-infection with hepatitis B virus genotype G","volume":"18","author":"Zaaijer","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0495","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3851\/IMP1887","article-title":"Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-\u03b12b: relation to response and HBV genotype","volume":"17","author":"Sonneveld","year":"2012","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0500","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.26436","article-title":"Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels","volume":"58","author":"Sonneveld","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0505","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1111\/jgh.12559","article-title":"Relationship between hepatitis B virus genotype B and C and response to interferon therapy in HBeAg positive chronic hepatitis B patients: A meta-analysis","volume":"29","author":"Kong","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0510","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0515","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1002\/hep.25636","article-title":"Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B","volume":"56","author":"Sonneveld","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0520","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1053\/jhep.2003.50458","article-title":"Determinants for sustained HBeAg response to lamivudine therapy","volume":"38","author":"Chien","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0525","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.3748\/wjg.v9.i12.2695","article-title":"Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment","volume":"9","author":"Chan","year":"2003","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.07.011_b0530","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1177\/135965350300800610","article-title":"Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine","volume":"8","author":"Yuen","year":"2003","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0535","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S0168-8278(05)81921-X","article-title":"The efficacy of entecavir is similar regardless of disease-related baseline subgroups in treatment of nucleoside-naive, HBeAg (+) and HBeAg (-) patients with chronic hepatitis B","volume":"42","author":"Lurie","year":"2005","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0540","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hep.22075","article-title":"Telbivudine vs. lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial","volume":"47","author":"Hou","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0545","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0016-5085(03)00700-5","article-title":"Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil","volume":"125","author":"Westland","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0550","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/hep.23905","article-title":"Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen\u2013positive patients","volume":"52","author":"Wursthorn","year":"2010","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0555","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/135965350801300217","article-title":"Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence","volume":"13","author":"Wiegand","year":"2008","journal-title":"Antiviral Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0560","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.jhep.2009.12.014","article-title":"Is response to antiviral treatment influenced by hepatitis B virus genotype?","volume":"52","author":"Raimondi","year":"2010","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0565","doi-asserted-by":"crossref","first-page":"672614","DOI":"10.1155\/2013\/672614","article-title":"HBV genotype B\/C and response to lamivudine therapy: a systematic review","volume":"2013","author":"Chen","year":"2013","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.jhep.2017.07.011_b0570","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3851\/IMP1454","article-title":"Hepatitis B virus genotype B has an earlier emergence of lamivudine resistance than genotype C","volume":"14","author":"Hsieh","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0575","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0168-8278(01)00283-5","article-title":"Is hepatitis B virus subtype testing useful in predicting virological response and resistance to lamivudine?","volume":"36","author":"Buti","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0580","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2009.08.063","article-title":"Hepatitis B virus resistance to nucleos (t) ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0585","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1056\/NEJMoa013215","article-title":"Hepatitis B e antigen and the risk of hepatocellular carcinoma","volume":"347","author":"Yang","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0590","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1053\/j.gastro.2005.11.016","article-title":"Risk evaluation of viral load elevation and associated liver disease\/cancer-in HBV (the REVEAL-HBV) Study Group Predicting cirrhosis risk based on the level of circulating hepatitis B viral load","volume":"130","author":"Iloeje","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0595","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.295.1.65","article-title":"Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level","volume":"295","author":"Chen","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jhep.2017.07.011_b0600","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/hep.21758","article-title":"Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients","volume":"46","author":"Hui","year":"2007","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0605","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.amjmed.2003.12.040","article-title":"Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels","volume":"116","author":"Chu","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0610","first-page":"1566","article-title":"Hepatitis and leukemia: their relation to Australia antigen","volume":"44","author":"Blumberg","year":"1968","journal-title":"Bull N Y Acad Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0615","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.amjmed.2005.02.033","article-title":"Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B","volume":"119","author":"Arase","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0620","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2014.07.019","article-title":"Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate","volume":"61","author":"Marcellin","year":"2014","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0625","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.jhep.2017.07.011_b0630","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s12072-015-9614-4","article-title":"Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years","volume":"9","author":"Buti","year":"2015","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0635","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1053\/j.gastro.2015.09.043","article-title":"Combination of tenofovir disoproxil fumarate and peginterferon \u03b1-2a increases loss of hepatitis B surface antigen in patients with chronic hepatitis B","volume":"150","author":"Marcellin","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2017.07.011_b0640","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1093\/jac\/dkm187","article-title":"Emergence of hepatitis B virus quasispecies with lower susceptibility to nucleos (t) ide analogues during lamivudine treatment","volume":"60","author":"Moriconi","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jhep.2017.07.011_b0645","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1111\/j.1365-2893.2007.00877.x","article-title":"Hepatitis B virus polymerase variants associated with entecavir drug resistance in treatment-naive patients","volume":"14","author":"Jardi","year":"2007","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0650","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1002\/jmv.21595","article-title":"Dynamic changes of HBV quasispecies and deletion patterns in a chronic hepatitis B patient","volume":"81","author":"Ji","year":"2009","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0655","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1086\/597808","article-title":"Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)\u2013treated patients and NRTI-naive patients","volume":"199","author":"Margeridon-Thermet","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jhep.2017.07.011_b0660","doi-asserted-by":"crossref","first-page":"e35052","DOI":"10.1371\/journal.pone.0035052","article-title":"Dynamics of hepatitis B virus quasispecies in association with nucleos (t) ide analogue treatment determined by ultra-deep sequencing","volume":"7","author":"Nishijima","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.07.011_b0665","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/1471-2180-12-307","article-title":"Whole genome HBV deletion profiles and the accumulation of preS deletion mutant during antiviral treatment","volume":"12","author":"Zhang","year":"2012","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jhep.2017.07.011_b0670","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/jmv.23530","article-title":"High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates","volume":"85","author":"Neumann-Fraune","year":"2013","journal-title":"J Med Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0675","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.meegid.2015.05.013","volume":"33","author":"Hao","year":"2015","journal-title":"Infect Gen Evol"},{"key":"10.1016\/j.jhep.2017.07.011_b0680","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1099\/jgv.0.000285","article-title":"Resistant mutations and quasispecies complexity of hepatitis B virus during telbivudine treatment","volume":"96","author":"Yin","year":"2015","journal-title":"J Gen Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0685","doi-asserted-by":"crossref","first-page":"e2614","DOI":"10.1097\/MD.0000000000002614","article-title":"Dynamics of Genotypic Mutations of the Hepatitis B Virus Associated With Long-Term Entecavir Treatment Determined With Ultradeep Pyrosequencing: A Retrospective Observational Study","volume":"95","author":"Zhang","year":"2016","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2017.07.011_b0690","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.cmi.2014.10.004","article-title":"Dynamics of hepatitis B virus quasispecies heterogeneity in association with nucleos (t) ide analogue treatment determined by MALDI-TOF MS","volume":"21","author":"Rybicka","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2017.07.011_b0695","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/1471-2180-12-96","article-title":"Detection of mixed populations of wild-type and YMDD hepatitis B variants by pyrosequencing in acutely and chronically infected patients","volume":"12","author":"Mello","year":"2012","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jhep.2017.07.011_b0700","doi-asserted-by":"crossref","first-page":"e37874","DOI":"10.1371\/journal.pone.0037874","article-title":"Ultra-deep pyrosequencing detects conserved genomic sites and quantifies linkage of drug-resistant amino acid changes in the hepatitis B virus genome","volume":"7","author":"Rodriguez-Fr\u00edas","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.07.011_b0705","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep.26383","article-title":"Characterization of the dynamics of hepatitis B virus resistance to adefovir by ultra-deep pyrosequencing","volume":"58","author":"Rodriguez","year":"2013","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0710","doi-asserted-by":"crossref","first-page":"387","DOI":"10.3851\/IMP2938","article-title":"HBV carrying drug-resistance mutations in chronically infected treatment-naive patients","volume":"20","author":"Gomes-Gouv\u00eaa","year":"2015","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0715","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11262-013-0915-1","article-title":"Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy","volume":"47","author":"Deng","year":"2013","journal-title":"Virus Genes"},{"key":"10.1016\/j.jhep.2017.07.011_b0720","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.virusres.2013.08.003","article-title":"Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy","volume":"177","author":"Zhang","year":"2013","journal-title":"Virus Res"},{"key":"10.1016\/j.jhep.2017.07.011_b0725","doi-asserted-by":"crossref","first-page":"130384","DOI":"10.1155\/2013\/130384","article-title":"Absence of hepatitis B resistance mutants before introduction of oral antiviral therapy","volume":"2013","author":"Moehlen","year":"2013","journal-title":"ISRN Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0730","doi-asserted-by":"crossref","first-page":"e212","DOI":"10.1111\/j.1365-2893.2011.01435.x","article-title":"Large-scale survey of naturally occurring HBV polymerase mutations associated with anti-HBV drug resistance in untreated patients with chronic hepatitis B","volume":"18","author":"Mirandola","year":"2011","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0735","doi-asserted-by":"crossref","first-page":"753","DOI":"10.3748\/wjg.15.753","article-title":"Hepatitis B virus mutations potentially conferring adefovir\/tenofovir resistance in treatment-naive patients","volume":"15","author":"Pastor","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.jhep.2017.07.011_b0740","doi-asserted-by":"crossref","first-page":"e0123139","DOI":"10.1371\/journal.pone.0123139","article-title":"New point mutations in surface and core genes of hepatitis B virus associated with acute on chronic liver failure identified by complete genomic sequencing","volume":"10","author":"Xu","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.07.011_b0745","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1177\/135965350901400504","article-title":"Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudine-resistant chronic hepatitis B patients","volume":"14","author":"Pollicino","year":"2009","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0750","doi-asserted-by":"crossref","first-page":"70264","DOI":"10.18632\/oncotarget.11840","article-title":"Pre-existing mutations related to tenofovir in chronic hepatitis B patients with long-term nucleos (t) ide analogue drugs treatment by ultra-deep pyrosequencing","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jhep.2017.07.011_b0755","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jhep.2008.12.018","article-title":"Early changes of hepatitis B virus quasispecies during lamivudine treatment and the correlation with antiviral efficacy","volume":"50","author":"Chen","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0760","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1136\/gut.2010.226225","article-title":"Evolutionary patterns of hepatitis B virus quasispecies under different selective pressures: correlation with antiviral efficacy","volume":"60","author":"Liu","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b0765","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.jhep.2013.05.038","article-title":"Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir\/emtricitabine combination or tenofovir monotherapy","volume":"59","author":"Lavocat","year":"2013","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0770","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1111\/jvh.12013","article-title":"Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs","volume":"20","author":"Peveling-Oberhag","year":"2013","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b0775","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.antiviral.2013.06.020","article-title":"Complexity and diversity of hepatitis B virus quasispecies: correlation with long-term entecavir antiviral efficacy","volume":"99","author":"Tong","year":"2013","journal-title":"Antiviral Res"},{"key":"10.1016\/j.jhep.2017.07.011_b0780","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.cmi.2015.03.021","article-title":"Prediction of virological response by pretreatment hepatitis B virus reverse transcriptase quasispecies heterogeneity: the advantage of using next-generation sequencing","volume":"21","author":"Han","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2017.07.011_b0785","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3851\/IMP2700","article-title":"Slow response to entecavir treatment in treatment-naive HBV patients is conditioned by immune response rather than by the presence or selection of refractory variants","volume":"19","author":"Solmone","year":"2014","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jhep.2017.07.011_b0790","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4254\/wjh.v7.i8.1086","article-title":"Clinical relevance of hepatitis B virus variants","volume":"7","author":"Gao","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0795","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/rmv.1897","article-title":"Current molecular methods for the detection of hepatitis B virus quasispecies","volume":"26","author":"Rybicka","year":"2016","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0800","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/j.bbadis.2014.06.015","article-title":"Next generation sequencing technology: advances and applications","volume":"1842","author":"Buermans","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.jhep.2017.07.011_b0805","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.tig.2014.07.001","article-title":"Ten years of next-generation sequencing technology","volume":"30","author":"Van Dijk","year":"2014","journal-title":"Trends Genet"},{"key":"10.1016\/j.jhep.2017.07.011_b0810","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/nrg.2016.49","article-title":"Coming of age: ten years of next-generation sequencing technologies","volume":"17","author":"Goodwin","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhep.2017.07.011_b0815","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1038\/537S54a","article-title":"Technology: Read the instructions","volume":"537","author":"Scott","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.jhep.2017.07.011_b0820","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/nrg.2016.86","article-title":"Towards precision medicine","volume":"17","author":"Ashley","year":"2016","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.jhep.2017.07.011_b0825","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.coviro.2011.07.008","article-title":"Ultra-deep sequencing for the analysis of viral populations","volume":"1","author":"Beerenwinkel","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.jhep.2017.07.011_b0830","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.meegid.2014.11.026","article-title":"Within-host nucleotide diversity of virus populations: insights from next-generation sequencing","volume":"30","author":"Nelson","year":"2015","journal-title":"Infect Genet Evol"},{"key":"10.1016\/j.jhep.2017.07.011_b0835","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.virol.2016.03.017","article-title":"Viral quasispecies complexity measures","volume":"493","author":"Gregori","year":"2016","journal-title":"Virology"},{"key":"10.1016\/j.jhep.2017.07.011_b0840","doi-asserted-by":"crossref","first-page":"E15","DOI":"10.3390\/pharmaceutics8020015","article-title":"Challenges, solutions, and quality metrics of personal genome assembly in advancing precision medicine","volume":"8","author":"Xiao","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jhep.2017.07.011_b0845","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.gdata.2015.07.018","article-title":"Genomic and transcriptome profiling identified both human and HBV genetic variations and their interactions in Chinese hepatocellular carcinoma","volume":"6","author":"Dong","year":"2015","journal-title":"Genom data"},{"key":"10.1016\/j.jhep.2017.07.011_b0850","doi-asserted-by":"crossref","first-page":"R182","DOI":"10.1093\/hmg\/ddw214","article-title":"Mission critical: the need for proteomics in the era of next-generation sequencing and precision medicine","volume":"25","author":"Cayer","year":"2016","journal-title":"Human Mol Genet"},{"key":"10.1016\/j.jhep.2017.07.011_b0855","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1373\/clinchem.2015.239475","article-title":"Mass spectrometry in precision medicine: phenotypic measurements alongside pharmacogenomics","volume":"62","author":"Clarke","year":"2016","journal-title":"Clin Chem"},{"key":"10.1016\/j.jhep.2017.07.011_b0860","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13059-016-0917-0","article-title":"The real cost of sequencing: scaling computation to keep pace with data generation","volume":"17","author":"Muir","year":"2016","journal-title":"Genome Biol"},{"key":"10.1016\/j.jhep.2017.07.011_b0865","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/nrclinonc.2015.204","article-title":"Computational oncology\u2013mathematical modelling of drug regimens for precision medicine","volume":"13","author":"Barbolosi","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jhep.2017.07.011_b0870","doi-asserted-by":"crossref","first-page":"904541","DOI":"10.1155\/2015\/904541","article-title":"Trends in it innovation to build a next generation bioinformatics solution to manage and analyse biological big data produced by NGS technologies","volume":"2015","author":"de Brevern","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0875","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/pmic.201500396","article-title":"Integrative methods for analyzing big data in precision medicine","volume":"16","author":"Gligorijevi\u0107","year":"2016","journal-title":"Proteomics"},{"key":"10.1016\/j.jhep.2017.07.011_b0880","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ymeth.2016.09.002","article-title":"Modeling and interoperability of heterogeneous genomic big data for integrative processing and querying","volume":"111","author":"Masseroli","year":"2016","journal-title":"Methods"},{"key":"10.1016\/j.jhep.2017.07.011_b0885","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1002\/1873-3468.12307","article-title":"Protein function in precision medicine: deep understanding with machine learning","volume":"590","author":"Rost","year":"2016","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jhep.2017.07.011_b0890","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.drudis.2013.10.012","article-title":"Big data in biomedicine","volume":"19","author":"Costa","year":"2014","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.jhep.2017.07.011_b0895","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s11886-013-0441-8","article-title":"Artificial intelligence in medicine and cardiac imaging: harnessing big data and advanced computing to provide personalized medical diagnosis and treatment","volume":"16","author":"Dilsizian","year":"2014","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.jhep.2017.07.011_b0900","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12920-015-0108-y","article-title":"From big data analysis to personalized medicine for all: challenges and opportunities","volume":"8","author":"Alyass","year":"2015","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.jhep.2017.07.011_b0905","first-page":"370194","article-title":"Big data analytics in healthcare","volume":"2105","author":"Belle","year":"2015","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0910","first-page":"107","article-title":"\u201cBig data\u201d and \u201copen data\u201d: What kind of access should researchers enjoy?","volume":"71","author":"Chatellier","year":"2016","journal-title":"Th\u00e9rapie"},{"key":"10.1016\/j.jhep.2017.07.011_b0915","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMp1606181","article-title":"Predicting the future-big data, machine learning, and clinical medicine","volume":"375","author":"Obermeyer","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2017.07.011_b0920","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/liv.12719","article-title":"Optimal therapy of chronic hepatitis B: how do I treat HBeAg-positive patients?","volume":"35","author":"Vlachogiannakos","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0925","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/gutjnl-2014-307023","article-title":"Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians","volume":"64","author":"Arends","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b0930","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2015.11.035","article-title":"PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy","volume":"64","author":"Papatheodoridis","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0935","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/hep.28115","article-title":"Validation of hepatitis B virus\u2013related hepatocellular carcinoma prediction models in the era of antiviral therapy","volume":"62","author":"Jung","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0940","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s12072-012-9365-4","article-title":"Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update","volume":"6","author":"Liaw","year":"2012","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0945","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/hep.28156","article-title":"AASLD guidelines for treatment of chronic hepatitis B","volume":"63","author":"Terrault","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0950","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1111\/liv.12768","article-title":"An intrahepatic transcriptional signature of enhanced immune activity predicts response to peginterferon in chronic hepatitis B","volume":"35","author":"Jansen","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2017.07.011_b0955","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jhep.2016.12.024","article-title":"Intrahepatic innate immune response pathways are downregulated in untreated chronic hepatitis B","volume":"66","author":"Leboss\u00e9","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b0960","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0092-8674(86)90602-1","article-title":"Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells","volume":"47","author":"Tuttleman","year":"1986","journal-title":"Cell"},{"key":"10.1016\/j.jhep.2017.07.011_b0965","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jhep.2017.07.011_b0970","doi-asserted-by":"crossref","first-page":"E56","DOI":"10.3390\/v9030056","article-title":"Complete and incomplete hepatitis B virus particles: Formation, function, and application","volume":"9","author":"Hu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.jhep.2017.07.011_b0975","doi-asserted-by":"crossref","first-page":"21713","DOI":"10.1074\/jbc.M501564200","article-title":"Hepatitis B virus DNA-negative dane particles lack core protein but contain a 22-kDa precore protein without C-terminal arginine-rich domain","volume":"280","author":"Kimura","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.jhep.2017.07.011_b0980","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.cmi.2015.02.010","article-title":"Hepatitis B core-related antigen (HBcrAg) levels in the natural history of hepatitis B virus infection in a large European cohort predominantly infected with genotypes A and D","volume":"21","author":"Maasoumy","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.jhep.2017.07.011_b0985","first-page":"58A","article-title":"Hepatitis B-core related antigen correlates with intrahepatic covalently closed circular DNA (cccDNA) levels and activity in untreated chronic hepatitis b (CHB) patients","volume":"64","author":"Testoni","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b0990","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hepr.12108","article-title":"Guidelines for avoiding risks resulting from discontinuation of nucleoside\/nucleotide analogs in patients with chronic hepatitis B","volume":"44","author":"Tanaka","year":"2014","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2017.07.011_b0995","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1111\/jvh.12565","article-title":"Baseline HBsAg and HBcrAg titres allow peginterferon-based \u2018\u2018precision medicine\u201d in HBeAg-negative chronic hepatitis B patients","volume":"23","author":"Martinot-Peignoux","year":"2016","journal-title":"J Viral Hepat"},{"key":"10.1016\/j.jhep.2017.07.011_b1000","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.jhep.2016.05.029","article-title":"Serum hepatitis B virus RNA is encapsidated pregenome RNA that may be associated with persistence of viral infection and rebound","volume":"65","author":"Wang","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b1005","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jhep.2016.09.028","article-title":"Serum HBV pgRNA as a clinical marker for cccDNA activity","volume":"66","author":"Giersch","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2017.07.011_b1010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/hep.27381","article-title":"Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors","volume":"61","author":"Van Bommel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2017.07.011_b1015","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1136\/gutjnl-2013-306228","article-title":"Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas","volume":"64","author":"Amaddeo","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b1020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrc3449","article-title":"Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma","volume":"13","author":"Arzumanyan","year":"2013","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jhep.2017.07.011_b1025","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S0009-8981(01)00644-1","article-title":"AFP-L3: a new generation of tumor marker for hepatocellular carcinoma","volume":"313","author":"Li","year":"2001","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.jhep.2017.07.011_b1030","first-page":"529314","article-title":"Diagnostic performance of des-\u03b3-carboxy prothrombin for hepatocellular carcinoma: A meta-analysis","author":"Zhu","year":"2014","journal-title":"Gastroenterol Res Pract"},{"key":"10.1016\/j.jhep.2017.07.011_b1035","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.clinre.2014.06.008","article-title":"Comparison osteopontin vs. AFP for the diagnosis of HCC: a meta-analysis","volume":"38","author":"Wan","year":"2014","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2017.07.011_b1040","first-page":"3655","article-title":"Diagnosis accuracy of serum Glypican-3 level in patients with hepatocellular carcinoma and liver cirrhosis: a meta-analysis","volume":"19","author":"Liu","year":"2015","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.jhep.2017.07.011_b1045","doi-asserted-by":"crossref","first-page":"e659","DOI":"10.1097\/MD.0000000000000659","article-title":"Serum Golgi protein 73 (GP73) is a diagnostic and prognostic marker of chronic HBV liver disease","volume":"94","author":"Xu","year":"2015","journal-title":"Medicine"},{"key":"10.1016\/j.jhep.2017.07.011_b1050","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1136\/gut.2010.214916","article-title":"Golgi protein 73 (GOLPH2) is a valuable serum marker for hepatocellular carcinoma","volume":"59","author":"Mao","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b1055","doi-asserted-by":"crossref","first-page":"e0140067","DOI":"10.1371\/journal.pone.0140067","article-title":"Diagnostic value of the combination of golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: a meta-analysis","volume":"10","author":"Dai","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jhep.2017.07.011_b1060","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/jcp.25135","article-title":"Systematic review and meta-analysis: circulating miRNAs for diagnosis of hepatocellular carcinoma","volume":"231","author":"Huang","year":"2016","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.jhep.2017.07.011_b1065","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1136\/gutjnl-2015-310686","article-title":"The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B","volume":"65","author":"Hu","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2017.07.011_b1070","first-page":"36","article-title":"Design of a clinical decision support system framework for the diagnosis and prediction of hepatitis B","volume":"4","author":"Adekunle","year":"2015","journal-title":"Int J Comput Appl Technol Res"},{"key":"10.1016\/j.jhep.2017.07.011_b1075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1440-1746.2010.06541.x","article-title":"The clinical implications of hepatitis B virus genotype: Recent advances","volume":"26","author":"Lin","year":"2011","journal-title":"J Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817321542?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827817321542?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T17:00:08Z","timestamp":1750784408000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827817321542"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":215,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["S0168827817321542"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2017.07.011","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How viral genetic variants and genotypes influence disease and treatment outcome of chronic hepatitis B. Time for an individualised approach?","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2017.07.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}